Literature DB >> 24666275

The effect of types I and III interferons on adrenocortical cells and its possible implications for autoimmune Addison's disease.

A Hellesen1, K Edvardsen, L Breivik, E S Husebye, E Bratland.   

Abstract

Autoimmune Addison's disease (AAD) is caused by selective destruction of the hormone-producing cells of the adrenal cortex. As yet, little is known about the potential role played by environmental factors in this process. Type I and/or type III interferons (IFNs) are signature responses to virus infections, and have also been implicated in the pathogenesis of autoimmune endocrine disorders such as type 1 diabetes and autoimmune thyroiditis. Transient development of AAD and exacerbation of established or subclinical disease, as well as the induction of autoantibodies associated with AAD, have been reported following therapeutic administration of type I IFNs. We therefore hypothesize that exposure to such IFNs could render the adrenal cortex susceptible to autoimmune attack in genetically predisposed individuals. In this study, we investigated possible immunopathological effects of type I and type III IFNs on adrenocortical cells in relation to AAD. Both types I and III IFNs exerted significant cytotoxicity on NCI-H295R adrenocortical carcinoma cells and potentiated IFN-γ- and polyinosine-polycytidylic acid [poly (I : C)]-induced chemokine secretion. Furthermore, we observed increased expression of human leucocyte antigen (HLA) class I molecules and up-regulation of 21-hydroxylase, the primary antigenic target in AAD. We propose that these combined effects could serve to initiate or aggravate an ongoing autoimmune response against the adrenal cortex in AAD.
© 2014 British Society for Immunology.

Entities:  

Keywords:  21-hydroxylase; Addison's disease; CXC chemokine ligand 10; interferon; polyinosine-polycytidylic acid

Mesh:

Substances:

Year:  2014        PMID: 24666275      PMCID: PMC4008979          DOI: 10.1111/cei.12291

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  63 in total

1.  Increased level of interferon-alpha in blood of patients with insulin-dependent diabetes mellitus: relationship with coxsackievirus B infection.

Authors:  W Chehadeh; J Weill; M C Vantyghem; G Alm; J Lefèbvre; P Wattré; D Hober
Journal:  J Infect Dis       Date:  2000-06-05       Impact factor: 5.226

2.  IL-28, IL-29 and their class II cytokine receptor IL-28R.

Authors:  Paul Sheppard; Wayne Kindsvogel; Wenfeng Xu; Katherine Henderson; Stacy Schlutsmeyer; Theodore E Whitmore; Rolf Kuestner; Ursula Garrigues; Carl Birks; Jenny Roraback; Craig Ostrander; Dennis Dong; Jinu Shin; Scott Presnell; Brian Fox; Betty Haldeman; Emily Cooper; David Taft; Teresa Gilbert; Francis J Grant; Monica Tackett; William Krivan; Gary McKnight; Chris Clegg; Don Foster; Kevin M Klucher
Journal:  Nat Immunol       Date:  2002-12-02       Impact factor: 25.606

Review 3.  Adrenocortical stem and progenitor cells: unifying model of two proposed origins.

Authors:  Michelle A Wood; Gary D Hammer
Journal:  Mol Cell Endocrinol       Date:  2010-11-20       Impact factor: 4.102

4.  Differential expression and action of Toll-like receptors in human adrenocortical cells.

Authors:  Waldemar Kanczkowski; Kai Zacharowski; Manfred P Wirth; Monika Ehrhart-Bornstein; Stefan R Bornstein
Journal:  Mol Cell Endocrinol       Date:  2008-10-31       Impact factor: 4.102

5.  Distinct clinical courses in type 1 diabetes mellitus induced by peg-interferon-alpha treatment for chronic hepatitis C.

Authors:  Masanori Yamazaki; Ai Sato; Teiji Takeda; Mitsuhisa Komatsu
Journal:  Intern Med       Date:  2010-03-01       Impact factor: 1.271

6.  Investigation on human adrenocortical cell response to adenovirus and adenoviral vector infection.

Authors:  Urska Matkovic; Monia Pacenti; Marta Trevisan; Giorgio Palù; Luisa Barzon
Journal:  J Cell Physiol       Date:  2009-07       Impact factor: 6.384

7.  Interferon-alpha initiates type 1 diabetes in nonobese diabetic mice.

Authors:  Qing Li; Baohui Xu; Sara A Michie; Kathleen H Rubins; Robert D Schreriber; Hugh O McDevitt
Journal:  Proc Natl Acad Sci U S A       Date:  2008-08-20       Impact factor: 11.205

8.  [A case of Addison's disease which became worse during interferon therapy: insulin secretion under hyposmolarity].

Authors:  K Oshimoto; H Shimizu; N Sato; M Mori
Journal:  Nihon Naibunpi Gakkai Zasshi       Date:  1994-06-20

9.  Thyroid disorders in chronic hepatitis C.

Authors:  Alessandro Antonelli; Clodoveo Ferri; Alessandro Pampana; Poupak Fallahi; Claudia Nesti; Martina Pasquini; Santino Marchi; Ele Ferrannini
Journal:  Am J Med       Date:  2004-07-01       Impact factor: 4.965

10.  Interferon-lambda1 induces peripheral blood mononuclear cell-derived chemokines secretion in patients with systemic lupus erythematosus: its correlation with disease activity.

Authors:  Qian Wu; Qingrui Yang; Elaine Lourenco; Hongsheng Sun; Yuanchao Zhang
Journal:  Arthritis Res Ther       Date:  2011-06-16       Impact factor: 5.156

View more
  6 in total

Review 1.  The potential role for infections in the pathogenesis of autoimmune Addison's disease.

Authors:  A Hellesen; E Bratland
Journal:  Clin Exp Immunol       Date:  2018-09-30       Impact factor: 4.330

2.  Peripheral Blood Cells from Patients with Autoimmune Addison's Disease Poorly Respond to Interferons In Vitro, Despite Elevated Serum Levels of Interferon-Inducible Chemokines.

Authors:  Kine Edvardsen; Trine Bjånesøy; Alexander Hellesen; Lars Breivik; Marit Bakke; Eystein S Husebye; Eirik Bratland
Journal:  J Interferon Cytokine Res       Date:  2015-05-15       Impact factor: 2.607

3.  Polymorphisms of the Toll-Like Receptor-3 Gene in Autoimmune Adrenal Failure and Type 1 Diabetes in Polish Patients.

Authors:  Marta Fichna; Magdalena Żurawek; Piotr Fichna; Danuta Januszkiewicz-Lewandowska; Marek Ruchała; Jerzy Nowak
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  2015-08-30       Impact factor: 4.291

Review 4.  Type I IFN family members: similarity, differences and interaction.

Authors:  Maria Rosaria Capobianchi; Elena Uleri; Claudia Caglioti; Antonina Dolei
Journal:  Cytokine Growth Factor Rev       Date:  2014-10-31       Impact factor: 7.638

5.  Analysis of cellular and humoral immune responses against cytomegalovirus in patients with autoimmune Addison's disease.

Authors:  Kine Edvardsen; Alexander Hellesen; Eystein S Husebye; Eirik Bratland
Journal:  J Transl Med       Date:  2016-03-09       Impact factor: 5.531

6.  Impact of Month of Birth on the Risk of Development of Autoimmune Addison's Disease.

Authors:  Agnieszka Pazderska; Marta Fichna; Anna L Mitchell; Catherine M Napier; Earn Gan; Marek Ruchała; Mauro Santibanez-Koref; Simon H Pearce
Journal:  J Clin Endocrinol Metab       Date:  2016-08-30       Impact factor: 5.958

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.